Kalvista Pharmaceuticals Stock News

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--EAACI 2022 accepts multiple abstracts from KalVista Pharmaceuticals, Inc.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

KalVista Pharmaceuticals (NASDAQ: KALV ) reported its Q3 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings KalVista Pharmaceuticals beat estimated earnings by 1.08%, reporting an EPS of … Full story available on Benzinga.com

KalVista Pharmaceuticals (KALV) began a phase 3 trial called KONFIDENT evaluating is potential oral drug KVD900 for hereditary angioedema ((HAE)) attacks.HAE is a disorder characterized…

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

KalVista Pharmaceuticals Inc (KALV) shares closed 0.1% lower than its previous 52 week low, giving the company a market cap of $304M. The stock is currently down 5.9% year-to-date, down 23.2% over the past 12 months, and up 61.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 12.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 990.0% The company's stock price performance over the past 12 months lags the peer average by 45.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares, rose in value on Friday, 12/17/21, with the stock price up by 0.38% to the previous days close as strong demand from buyers drove the stock to $13.20. Actively observing the price movement in the last trading, the stock closed the session at $13.15, falling within a range of $12.85 KalVista Pharmaceuticals Inc. (NASDAQ: KALV) Is A Blank Check For Growth Read More »

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective lowered by Needham & Company LLC from $50.00 to $48.00 in a research note published on Friday morning, Stock Target Advisor reports. The firm currently has a buy rating on the specialty pharmaceutical companys stock. Several other brokerages have also weighed in on KALV. Zacks Investment Research upgraded []

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been given a consensus rating of Buy by the seven analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a []

KalVista Pharmaceuticals (NASDAQ:KALV) issued its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.80) EPS for the quarter, missing analysts consensus estimates of ($0.79) by ($0.01), Fidelity Earnings reports. Shares of NASDAQ:KALV opened at $13.73 on Friday. The businesss fifty day moving average price is $16.79 and its two-hundred day moving average price is []

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the announcement.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2021. This quarter we made great strides in advancing the two distinct compounds in our oral hereditary angioedema franchise into later sta

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned a consensus recommendation of Buy from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the []